Vanda Pharmaceuticals reported 16.79 in PE Price to Earnings for its fiscal quarter ending in June of 2023.





Pe Change Date
Acadia Pharmaceuticals 9.52 1.81 Sep/2026
Agios Pharmaceuticals 3.56 0 Mar/2026
Akebia Therapeutics 1.63K 1.6K Dec/2025
Alnylam Pharmaceuticals 13.17 62.47 Sep/2026
Anika Therapeutics 47.54 27.2 Jun/2024
Arrowhead Research 39.19 0 Jun/2026
AstraZeneca 24.63 0.71 Sep/2026
Bristol-Myers Squibb 10.44 5.7 Sep/2026
Eli Lilly 64.5 31.61 Sep/2026
Halozyme Therapeutics 16.12 3.61 Sep/2026
J&J 25.86 3.57 Sep/2026
Lexicon Pharmaceuticals 12.44 4.73 Jun/2021
Ligand Pharmaceuticals 68.1 16.21 Sep/2026
Merck 34.36 2.11 Sep/2026
Moderna 27.22 14.51 Jun/2023
Novartis 21.54 0.18 Sep/2026
Pfizer 15.2 3.72 Sep/2026
PTC Therapeutics 8.76 0 Jun/2026
Puma Biotechnology 13.93 44.88 Jun/2024
Sanofi 22.34 3.38 Sep/2026
Takeda 21.04 3.36 Sep/2026
Teva Pharmaceutical Industries 18.7 5.9 Sep/2026
Vanda Pharmaceuticals 16.79 7.07 Jun/2023
Veracyte 29.55 13.22 Sep/2026